• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Wave Life Sci Ord Sh (NQ: WVE )

    14.83 +0.63 (+4.44%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Wave Life Sci Ord Sh

    < Previous 1 2 3 4 5 Next >
    1 Brand-New Big Reason to Buy This Biotech Stock Right Now
    This stock currently has a good balance of risk and potential rewards. 
    Via The Motley Fool
    Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
    Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
    Via Investor's Business Daily
    Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
    These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
    Via Benzinga
    This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    What Analysts Are Saying About WAVE Life Sciences Stock
    Via Benzinga
    WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
    Via Benzinga
    Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
    Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
    Via Benzinga
    Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
    The company is testing its new technology in patients with a genetic disease that impacts the lungs. 
    Via Investor's Business Daily
    United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
    These two could become direct competitors relatively soon. 
    Via The Motley Fool
    General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Crude Oil Gains Over 1%; BioVie Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
    Via Benzinga
    Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
    Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and... 
    Via Benzinga
    Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
    William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
    Via Benzinga
    WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q2 2024
    WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    What's Going On With Wave Life Sciences Stock On Tuesday?
    Wave Life Sciences reports Phase 1b/2a SELECT-HD trial results for WVE-003 in Huntington's disease, demonstrates promise as a disease-modifying therapy. 
    Via Benzinga
    WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q1 2024
    WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. 
    Via Benzinga
    American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday
    U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. 
    Via Benzinga
    WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023
    WVE stock results show that WAVE Life Sciences beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Earnings Scheduled For March 6, 2024
    Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.